Matches in Nanopublications for { ?s ?p "[We retrospectively studied four cases of t-MDS/AML among 210 (1.9%) consecutive patients with CLL treated at a single center with fludarabine and cyclophosphamide (FC) either as the first- or second-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 10 of
10
with 100 items per page.
- NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_assertion description "[We retrospectively studied four cases of t-MDS/AML among 210 (1.9%) consecutive patients with CLL treated at a single center with fludarabine and cyclophosphamide (FC) either as the first- or second-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP605928.RARqHD9evW0UhDSQhJj0n6chhJ4bG9EU8F14EkSlKL-CE130_provenance.
- assertion description "[We retrospectively studied four cases of t-MDS/AML among 210 (1.9%) consecutive patients with CLL treated at a single center with fludarabine and cyclophosphamide (FC) either as the first- or second-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP911078.RAQwQj2INwcchtfm2FC4BpzIO7Bq9rSafiv43iU6pR9Jk130_assertion description "[We retrospectively studied four cases of t-MDS/AML among 210 (1.9%) consecutive patients with CLL treated at a single center with fludarabine and cyclophosphamide (FC) either as the first- or second-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP911078.RAQwQj2INwcchtfm2FC4BpzIO7Bq9rSafiv43iU6pR9Jk130_provenance.
- NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_assertion description "[We retrospectively studied four cases of t-MDS/AML among 210 (1.9%) consecutive patients with CLL treated at a single center with fludarabine and cyclophosphamide (FC) either as the first- or second-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_provenance.
- NP911087.RAWjte9NfWs13urCo74gNnJn6-M9Yzg2VX7WrhKr989g8130_assertion description "[We retrospectively studied four cases of t-MDS/AML among 210 (1.9%) consecutive patients with CLL treated at a single center with fludarabine and cyclophosphamide (FC) either as the first- or second-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP911087.RAWjte9NfWs13urCo74gNnJn6-M9Yzg2VX7WrhKr989g8130_provenance.
- NP978466.RAjolAE_qGCoeCZLasimVFizaBo1LJewWnFiH3m7IvQzE130_assertion description "[We retrospectively studied four cases of t-MDS/AML among 210 (1.9%) consecutive patients with CLL treated at a single center with fludarabine and cyclophosphamide (FC) either as the first- or second-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978466.RAjolAE_qGCoeCZLasimVFizaBo1LJewWnFiH3m7IvQzE130_provenance.
- NP911085.RAhC1pZflQ_kCgAAdwHqsx9QJ5u-OeShi1g6rjNGsG3PE130_assertion description "[We retrospectively studied four cases of t-MDS/AML among 210 (1.9%) consecutive patients with CLL treated at a single center with fludarabine and cyclophosphamide (FC) either as the first- or second-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP911085.RAhC1pZflQ_kCgAAdwHqsx9QJ5u-OeShi1g6rjNGsG3PE130_provenance.
- NP781374.RA9hKVujer4PDaN2RheJaW626F2JLGaXuNkPmxgzXZynQ130_assertion description "[We retrospectively studied four cases of t-MDS/AML among 210 (1.9%) consecutive patients with CLL treated at a single center with fludarabine and cyclophosphamide (FC) either as the first- or second-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781374.RA9hKVujer4PDaN2RheJaW626F2JLGaXuNkPmxgzXZynQ130_provenance.
- NP913958.RA6dUyG_GYFhC9cfND6SaLAORBqPSHHQTyfqvybia7OF8130_assertion description "[We retrospectively studied four cases of t-MDS/AML among 210 (1.9%) consecutive patients with CLL treated at a single center with fludarabine and cyclophosphamide (FC) either as the first- or second-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP913958.RA6dUyG_GYFhC9cfND6SaLAORBqPSHHQTyfqvybia7OF8130_provenance.
- NP911081.RA_PBpenicPb6hWlB40RgvMik15kTlyeEkxwcJBPe-Urw130_assertion description "[We retrospectively studied four cases of t-MDS/AML among 210 (1.9%) consecutive patients with CLL treated at a single center with fludarabine and cyclophosphamide (FC) either as the first- or second-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP911081.RA_PBpenicPb6hWlB40RgvMik15kTlyeEkxwcJBPe-Urw130_provenance.